| China | Turkey | Austria | |
| Stem cell treatment for multiple sclerosis (MS) | from $22,500 | from $12,000 | from $30,000 |
| Stem cell treatment for ADHD | from $19,500 | from $8,000 | from $18,000 |
| Stem cell therapy for spinal cord injury | from $21,500 | from $15,000 | from $70,000 |
| Stem cell therapy for neuropathy | from $19,500 | from $4,500 | from $18,000 |
| Stem cell therapy for male infertility | from $7,800 | from $4,500 | from $8,500 |
No hidden fees – just official clinic prices. Pay at the clinic for Stem Cells treatment upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Stem Cells treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Stem Cells treatment journey.
Professor Zheng Qiu Hong is Director of the Cell Therapy Research Center and a National Senior Expert in Biotherapy. He is a Professor and Master’s Supervisor at Fujian Medical University. He has more than 30 years of clinical experience in tumor molecular biology and biotherapy. From 2012 to 2013, he was a visiting scholar in stem cell research at the University of Connecticut School of Life Sciences. He previously held leadership roles at Fujian Cancer Hospital. These roles included Director of the Tumor Molecular Biology Laboratory and Director of the Surgical Oncology Research Laboratory. He also served as Deputy Director of the Fujian Key Laboratory of Tumor Biotherapy and Deputy Director of the Biotherapy and Immunotherapy Center.
Appointments include Standing Committee Member of the Biotherapy Committee of the Chinese Research Hospital Association. He is also a Committee Member of the Tumor Immunology and Biotherapy Committee of the Chinese Society for Immunology. In addition, he is Deputy Chair of the Academic Committee of the Xiamen Cell Therapy Research Center at the First Affiliated Hospital of Xiamen University.
Professor Liang Xiaoxiao is the Department Director and Chief Physician in Neurorehabilitation. She holds a master’s degree in neurology. She is skilled in neuromodulation for disorders of consciousness, cognition, and movement. Her focus includes cases from cerebrovascular disease, Parkinson’s disease, and related conditions. She also performs ultrasound-guided botulinum toxin injections for blepharospasm, hemifacial spasm, limb spasticity, sialorrhea, and neuralgia.
Accreditations and roles: Member of the Neurorehabilitation, Cognitive Disorder Rehabilitation, and Craniocerebral Trauma Rehabilitation Committees of the Chinese Association of Rehabilitation Medicine. Standing Member of the Cognitive Disorder Rehabilitation Committee of the Fujian Association of Rehabilitation Medicine. Vice Chair of the Dementia and Cognitive Disorder Committee of the Xiamen Preventive Medicine Association. Vice President of the Parkinson’s Disease and Movement Disorders Committee of the Xiamen Medical Doctor Association. Standing Member of the Neuromodulation Committee of the Xiamen Medical Doctor Association. Recipient of the Most Beautiful Physician of Xiamen City (2024).
Dr. Zhang Jin Nong is a national expert in infectious diseases at Xiamen Humanity Hospital. He serves as Director of Respiratory and Cardiovascular Medicine. Dr. Zhang received the Hubei Provincial Advanced Individual award for his pandemic control efforts. He treats complex cases of lung cancer, pneumonia, and chronic obstructive pulmonary disease.
Dr. Sean Hu is a leader in biotechnology and stem cell therapy. He earned a PhD in biochemistry and molecular biology from the University of Gothenburg and Chalmers University of Technology in Sweden. He is the founder, chairman, and CEO of Shenzhen Beike Biotechnology Co., Ltd. He also serves as director of the Shenzhen Beike Cell Engineering Institute.
He was among the first experts recognized by China’s Thousand Talents Program. At Beike, he leads the development and commercialization of adult stem cell therapies. His work focuses on conditions of the brain and spinal cord, and on neurodegenerative and autoimmune disorders. His goal is to make high-quality care more accessible.